{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:40:41Z","timestamp":1773297641106,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.clinthera.2015.12.020","type":"journal-article","created":{"date-parts":[[2016,2,9]],"date-time":"2016-02-09T04:45:17Z","timestamp":1454993117000},"page":"516-530","source":"Crossref","is-referenced-by-count":26,"title":["Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus"],"prefix":"10.1016","volume":"38","clinical-trial-number":[{"clinical-trial-number":"nct01088711","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Carol","family":"Addy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Tatosian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoli S.","family":"Glasgow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Isaias N.","family":"Gendrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunkyung","family":"Kauh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Martucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy O.","family":"Johnson-Levonas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Selverian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine Z.","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0967-7355","authenticated-orcid":false,"given":"Marie","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Aubrey Stoch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2015.12.020_bib1","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1210\/en.2010-0115","article-title":"Minireview: update on incretin biology: focus on glucagon-like peptide-1","volume":"151","author":"Brubaker","year":"2010","journal-title":"Endocrinol"},{"key":"10.1016\/j.clinthera.2015.12.020_bib2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.mce.2008.08.012","article-title":"The incretin system and its role in type 2 diabetes mellitus","volume":"297","author":"Holst","year":"2009","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.clinthera.2015.12.020_bib3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","article-title":"The biology of incretin hormones","volume":"3","author":"Drucker","year":"2006","journal-title":"Cell Metab"},{"key":"10.1016\/j.clinthera.2015.12.020_bib4","doi-asserted-by":"crossref","first-page":"428","DOI":"10.2337\/dc09-1499","article-title":"Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits","volume":"33","author":"Drucker","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2015.12.020_bib5","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.2337\/db09-1414","article-title":"The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action","volume":"59","author":"Hare","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2015.12.020_bib6","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1017\/S146239940900132X","article-title":"Molecular mechanisms underlying nutrient-stimulated incretin secretion","volume":"12","author":"Parker","year":"2010","journal-title":"Expert Rev Mol Med"},{"key":"10.1016\/j.clinthera.2015.12.020_bib7","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1172\/JCI30076","article-title":"The role of gut hormones in glucose homeostasis","volume":"117","author":"Drucker","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2015.12.020_bib8","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/j.1463-1326.2008.00887.x","article-title":"Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach","volume":"10","author":"Xu","year":"2008","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2015.12.020_bib9","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11892-003-0079-9","article-title":"Gut peptides and type 2 diabetes mellitus treatment","volume":"3","author":"Ahren","year":"2003","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.clinthera.2015.12.020_bib10","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1055\/s-2004-826160","article-title":"Circulation and degradation of GIP and GLP-1","volume":"36","author":"Deacon","year":"2004","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.clinthera.2015.12.020_bib11","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/j.1432-1033.1993.tb17986.x","article-title":"Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum","volume":"214","author":"Mentlein","year":"1993","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.clinthera.2015.12.020_bib12","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2015.12.020_bib13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1517\/13543784.12.1.87","article-title":"Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes","volume":"12","author":"Drucker","year":"2003","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.clinthera.2015.12.020_bib14","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.2337\/dc06-0703","article-title":"Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes","volume":"29","author":"Aschner","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2015.12.020_bib15","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1185\/030079907X188152","article-title":"Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes","volume":"23","author":"Hanefeld","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2015.12.020_bib16","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1007\/s00125-006-0416-z","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus","volume":"49","author":"Raz","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2015.12.020_bib17","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1742-1241.2006.01246.x","article-title":"Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes","volume":"61","author":"Scott","year":"2007","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.clinthera.2015.12.020_bib18","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.2337\/diabetes.53.9.2181","article-title":"Therapeutic strategies based on glucagon-like peptide 1","volume":"53","author":"Deacon","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2015.12.020_bib19","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1210\/jc.2006-1932","article-title":"The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion","volume":"92","author":"El Ouaghlidi","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2015.12.020_bib20","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1463-1326.2006.00704.x","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial","volume":"9","author":"Nauck","year":"2007","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2015.12.020_bib21","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1208\/s12248-008-9041-8","article-title":"Accelerating drug development using biomarkers: a case study with sitagliptin, a novel DPP4 inhibitor for type 2 diabetes","volume":"10","author":"Krishna","year":"2008","journal-title":"AAPS J"},{"key":"10.1016\/j.clinthera.2015.12.020_bib22","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1517\/14656566.2015.978289","article-title":"A review of gliptins for 2014","volume":"16","author":"Scheen","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clinthera.2015.12.020_bib23","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1021\/jm401992e","article-title":"Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes","volume":"57","author":"Biftu","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.clinthera.2015.12.020_bib24","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2337\/dc15-0109","article-title":"Safety and efficacy of omarigliptin (MK-3102), a novel once-weekly dpp-4 inhibitor for the treatment of patients with type 2 diabetes","volume":"38","author":"Sheu","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2015.12.020_bib25","unstructured":"Krishna R, Addy C, Tatosian D, et al. Single-\/multiple-dose pharmacokinetics (PK) and pharmacodynamics (PD) of omarigliptin, a once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in healthy subjects. Presented at the 73rd American Diabetes Association (ADA) Annual Scientific Session, Chicago, Illinois, 2013."},{"key":"10.1016\/j.clinthera.2015.12.020_bib26","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/clpt.2010.184","article-title":"Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1","volume":"88","author":"Migoya","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2015.12.020_bib27","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1517\/14728214.2013.807796","article-title":"Emerging gliptins for type 2 diabetes","volume":"18","author":"Cahn","year":"2013","journal-title":"Expert Opin Emerg Drugs"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291816000163?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291816000163?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T07:29:57Z","timestamp":1718350197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291816000163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S0149291816000163"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2015.12.020","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]}}}